936091-15-5

Basic information

• Product Name: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide
• Synonyms: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide;TG-46;N-(tert-Butyl)-3-((5-methyl-2-((4-(morpholinomethyl)phenyl)-amino)pyrimidin-4-yl)amino)benzene
• CAS NO: 936091-15-5
• Molecular Formula: C26H34N6O3S
• Molecular Weight: 511
• Mol File: 936091-15-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide(936091-15-5)
• EPA Substance Registry System: N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide(936091-15-5)

Safety Data

• Hazardous Substances Data: 936091-15-5(Hazardous Substances Data)

Usage

Description

N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide, also known as Pazopanib, is a medication that belongs to the class of tyrosine kinase inhibitors. It is used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. Pazopanib works by blocking the action of vascular endothelial growth factor receptor (VEGFR) and other proteins involved in the growth and spread of cancer cells. This medication is typically taken orally and is available as a tablet.

Uses

Used in Oncology:
Pazopanib is used as an anticancer agent for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. It functions by inhibiting the activity of VEGFR and other proteins that contribute to cancer cell growth and metastasis, thereby slowing down or stopping the progression of these diseases.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Pazopanib is used as a key component in the formulation of oral tablets for cancer treatment. Its development and production involve rigorous quality control and adherence to regulatory standards to ensure its safety and efficacy as a medication.

Upstream product

• 936092-53-4 N-(tert-butyl)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)benzenesulfonamide 
• 51013-67-3 4-morpholinomethyl aniline 

Relevant articles and documents

BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.